Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals.Mortality rates are as high as 90% due to limited treatments.The azole class antifungal, fluconazole, is widely available and has multi-species activity but only inhibits growth instead of killing fungal cells, necessitating long treatments.To R